Cerebrolysin as a nerve growth factor for treatment of acquired peripheral nervous system diseases

Neural Regeneration Research

Volumn 6, Issue 18, 2011, Pages 1415-1420

  Hamed, Sherifa Ahmad ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Cerebrolysin; Neuroprotection; Neurotrophic effect; Peripheral nervous system

Indexed keywords

AMANTADINE SULFATE; ANABOLIC AGENT; ANTIOXIDANT; CEREBROLYSIN; NERVE GROWTH FACTOR; PENTOXIFYLLINE; PYRIDOSTIGMINE; STEROID; THIOCTIC ACID; VITAMIN B COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; BIRTH INJURY; BRACHIAL PLEXUS NEUROPATHY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONVALESCENCE; DRUG EFFICACY; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; HYPOTONIC BLADDER; MALE; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; NEURITIS; OPHTHALMOPLEGIA; PARAPLEGIA; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; RADIAL NERVE PALSY; RADICULITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79960883167     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2011.18.010     Document Type: Article

References (36)

1. Aloe L. Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends Cell Biol. 2004;14:395-399.
2. Tessarollo L. Pleiotropic functions of neurotrophins in development. Cytokine Growth Factor Rev. 1998;9:125-137.
3. Veinbergs I, Mante M, Mallory M, et al. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl. 2000;59:273-280.
4. Hartbauer M, Hutter-Paier B, Skofitsch G, et al. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108: 459-473.
5. Ren JM, Finklestein SP. Growth factor treatment of stroke. Curr Drug Targets CNS Neurol Disord. 2005;4:119-123.
6. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88:3275-3281.
7. Satou T, Itoh T, Tamai Y, et al. Neurotrophic effects of FPF-1070 (cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks. J Neural Transm. 2000;107:1253-1262.
8. Gomazkov OA. Apoptosis in neuronal structures and the role of neurotrophic growth factors. Biochemical mechanisms of brain derived peptide preparations. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;Suppl 7:17-21.
9. Bae CY, Cho CY, Cho K, et al. A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer's disease. J Am Ger Soc. 2000;48:1566-1571.
10. Windisch M. Approach towards an integrative drug treatment of Alzheimer's disease. J Neural Transm Suppl. 2000;59:301-313.
11. Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent cerebrolysin. J Neural Transm Suppl. 2002;(62):277-285.
12. Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer's disease: A randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm. 2002;109:1089-1104.
13. Alvarez XA, Sampedro C, Pérez P, et al. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with post-acute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol. 2003;18: 271-278.
14. Ladurner G, Kalvach P, Moessler H, et al. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomized controlled trial. J Neural Transm. 2005;112:415-428.
15. Skwortsova VI, Stakhovskaia LV, Shamalov NA, et al. Results of the multicenter prospective study of cerebrolysin safety and efficacy in acute stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Suppl 16:41-45.
16. Damulin IV, Koberskaia NN, Mkhitarian EA. The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107:32-38.
17. Govorin NV, Zlova TP, Akhmetova VV, et al. The pathophysiological analysis of cerebrolysin therapy of children with mental developmental delay caused by ecological factors. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108:51-55.
18. Muresanu DF, Alvarez XA, Moessler H, et al. A pilot study to evaluate the effects of cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. J Neurol Sci. 2008;267:112-119.
19. Hong Z, Moessler H, Bornstein N, et al. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia-CASTA. Int J Stroke. 2009;4:406-412.
20. Bajenaru O, Tiu C, Moessler H, et al. Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. J Med Life. 2010; 3:137-143.
21. Jianu DC, Muresanu DF, Bajenaru O, et al. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. J Med Life. 2010;3:297-307.
22. Muresanu DF, Alvarez XA, Moessler H, et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. J Neurol Sci. 2010;299:179-183.
23. Guseva MR. Neuropeptides in the treatment of optic nerve atrophy in children. Zh Nevrol Psikhiatr Im S S Korsakova. 2010; 110:37-40.
24. Sugita Y, Kondo T, Kanazawa A, et al. Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil--detection of hydroxyl radicals with salicylic acid. No To Shinkei. 1993;45:325-331.
25. Gonzalez ME, Francis L, Castellano O. Antioxidant systemic effect of short-term Cerebrolysin administration. J Neural Transm. 1998;53:333-341.
26. Gaǐtetdinova DD, Semenov VV, Ismagilov MF, et al. Clastogenic, aneugenic, pro-and antioxidant properties of some neurotropic preparations. Eksp Klin Farmakol. 2006;69:58-62.
27. Tatebayashi Y, Lee MH, Li L, et al. The dentate gyrus neurogenesis. A therapeutic target for Alzheimer's disease. Acta Neuropathol. 2003:225-232.
28. Biesenbach G, Grafinger P, Eichbauer-Sturm G, et al. Cerebrolysin in treatment of painful diabetic neuropathy. Wien Med Wochenschr. 1997;147:63-66.
29. Melika LK. Wechsler Adult Intelligence Scale-revised Manual: Arabic Examiner's Handbook. Cairo: Dar Egyptian Books House. 1996.
30. Hamed SA. The multimodal prospects for neuroprotection and disease modification in epilepsy: relationship to its challenging neurobiology. Restor Neurol Neurosci. 2010;28:323-348.
31. Ubbink JB, Becker PJ, Vermaak WJ, et al. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem. 1995;41: 1033-1037.
32. Bunout D, Garrido A, Suazo M, et al. Effects of supplementation with folic acid and antioxidant vitamins on homocysteine levels and LDL oxidation in coronary patients. Nutrition. 2000;16(2): 107-110.
33. Earnest CP, Wood KA, Church TS. Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. J Am Coll Nutr. 2003;22:400-407.
34. Farvid MS, Siassi F, Jalali M, et al. The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes Res Clin Pract. 2004;65:21-28.
35. Haninec P, Houst'ava L, Stejskal L, et al. Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal administration of IGF-I and Cerebrolysin. Ann Anat. 2003;185: 233-238.
36. Andrews RJ. Neuroprotection trek--the next generation: neuromodulation II. Applications--epilepsy, nerve regeneration, neurotrophins. Ann N Y Acad Sci. 2003;993:14-24.